2022
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry
Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, Cautela J, Francis S, Courand PY, Deswal A, Ewer SM, Aras M, Arangalage D, Ghafourian K, Fenioux C, Finke D, Peretto G, Zaha V, Zadok O, Tajiri K, Akhter N, Levenson J, Baldassarre L, Power J, Huang S, Collet JP, Moslehi J, Salem JE, contributors I, Aghel N, Alexandre J, Aonuma K, Asnani A, Behling J, Bilen M, Bottinor W, Cariou E, Chahine J, Chan W, Chauhan A, Cohen M, Crusz S, Fernando S, Florido R, Frigeri M, Fukushima S, Gaughan E, Geisler B, Gilstrap L, Grohe C, Guha A, Habib M, Haegler-Laube E, Haydon A, Hayek S, Hughes A, Imai R, Katsume Y, Kimura H, Lin L, Lenneman C, Leong D, Makker V, Martinez-Calle N, Moey M, Mohri M, Morimoto R, Moritoki Y, Narezkina A, Nicol M, Nooka A, Orimoloye O, Patel M, Perl M, Piriou N, Raikhelkar J, Raza Y, Rao A, Reddy S, Seki N, Stangl K, Stewart A, Stringer B, Tamarappoo B, Tamura Y, Thuny F, Tierney S, Tresorier R, Ullah W, Von Hunolstein J, Warner E, Weppler A. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. European Journal Of Cancer 2022, 177: 197-205. PMID: 36030143, PMCID: PMC10165738, DOI: 10.1016/j.ejca.2022.07.018.Peer-Reviewed Original ResearchMeSH KeywordsCoronary Artery DiseaseHumansImmune Checkpoint InhibitorsMyocarditisPrognosisRegistriesRetrospective StudiesRisk FactorsConceptsCoronary artery diseaseImmune checkpoint blockersCoronary revascularizationArtery diseaseCAD groupInternational registryPrompt clinical diagnosisAcute coronary syndromeCoronary artery stenosisAdjustment of ageCause deathCoronary syndromeIndex hospitalisationSteroid administrationCheckpoint blockersCoronary angiographyArtery stenosisCoronary angiogramPoor outcomeSevere presentationRevascularizationPatientsCardiac pathologyClinical diagnosisMyocarditis
2021
Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity
Higgins AY, Arbune A, Soufer A, Ragheb E, Kwan JM, Lamy J, Henry M, Cuomo JR, Charifa A, Gallegos C, Hull S, Coviello JS, Bader AS, Peters DC, Huber S, Mojibian HR, Sinusas AJ, Kluger H, Baldassarre LA. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLOS ONE 2021, 16: e0246764. PMID: 33606757, PMCID: PMC7895343, DOI: 10.1371/journal.pone.0246764.Peer-Reviewed Original ResearchConceptsGlobal longitudinal strainImmune checkpoint inhibitorsLate gadolinium enhancementRecovery of LVEFLake Louise criteriaCheckpoint inhibitorsNormal LVEFAverage global longitudinal strainPresence of LGEAbnormal global longitudinal strainCardiac magnetic resonance imagingCorrect clinical contextEvaluation of myocarditisLeft ventricular dysfunctionVentricular ejection fractionDiagnosis of myocarditisLeft ventricular strainCardiac magnetic resonanceLeft ventricular myocardial strainOvert left ventricular dysfunctionVentricular myocardial strainMagnetic resonance imagingAtrial strainVentricular dysfunctionVentricular strain